Respiratory Research Analysis
May’s respiratory research converged on mechanistic disease drivers and near-term translational options. Highlights include an epithelial lipid–ER–mitochondrial axis (CEPT1) that explains asthma epithelial dysfunction, and large randomized trials showing IL-33/ST2 blockade (astegolimab) reduces COPD exacerbations broadly. Neuroscience advanced with astrocyte control of hypoxia-linked breathing–arousal coupling, while clinical prevention progressed via a phase 3 RCT of oral ensitrelvir for COVID-
Summary
May’s respiratory research converged on mechanistic disease drivers and near-term translational options. Highlights include an epithelial lipid–ER–mitochondrial axis (CEPT1) that explains asthma epithelial dysfunction, and large randomized trials showing IL-33/ST2 blockade (astegolimab) reduces COPD exacerbations broadly. Neuroscience advanced with astrocyte control of hypoxia-linked breathing–arousal coupling, while clinical prevention progressed via a phase 3 RCT of oral ensitrelvir for COVID-19 postexposure prophylaxis. Finally, immune-oncology concepts entered fibrosis, with NK-directed strategies targeting the HLA-E–NKG2A checkpoint reversing fibrosis in preclinical models.
Selected Articles
1. FOXA1-mediated CEPT1 deficiency in airway epithelium drives asthma via an ER stress-mitochondrial dysfunction axis.
This mechanistic study links CEPT1 downregulation in asthmatic airway epithelium to phospholipid imbalance, pan-ER stress activation, ER Ca2+ disruption, and mitochondrial dysfunction, establishing a FOXA1–CEPT1 regulatory axis.
Impact: Identifies a druggable epithelial lipid–ER–mitochondria axis explaining asthma epithelial dysfunction and nominating CEPT1 as a precision target/biomarker.
Clinical Implications: Supports development of therapies to restore phosphatidylcholine balance, upregulate CEPT1, or mitigate ER/mitochondrial stress; CEPT1 expression may enable patient stratification.
Key Findings
- CEPT1 is significantly downregulated in asthmatic airway epithelium.
- Phospholipid imbalance activates all three ER stress branches and disrupts ER Ca2+ homeostasis.
- Mitochondrial dysfunction links epithelial metabolic defects to asthma pathophysiology.
2. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.
Two large RCTs show astegolimab (anti-ST2) reduces annualized moderate/severe COPD exacerbations versus placebo with balanced safety, independent of baseline eosinophil counts.
Impact: Provides near-practice-changing evidence for IL-33/ST2 pathway blockade as a biologic option for frequent-exacerbator COPD patients regardless of eosinophil status.
Clinical Implications: Astegolimab could be integrated as add-on therapy for frequent-exacerbation COPD pending regulatory review and biomarker refinement.
Key Findings
- Astegolimab reduced moderate/severe exacerbations across trials and dosing schedules.
- Efficacy was observed across eosinophil strata.
- Adverse events and mortality were balanced, supporting acceptable safety.
3. Astrocyte activation in the ventrolateral medulla modulates breathing and arousal states.
In awake mice, ventral respiratory-column astrocytes activate before sighs and during hypoxia; targeted activation increases sigh-linked arousals and enhances catecholaminergic neuronal activity, defining a causal astrocyte–neuronal mechanism.
Impact: Reveals astrocytes as active modulators of hypoxia-evoked breathing–arousal coupling, informing mechanistic bases of sleep-disordered breathing and arousal pathologies.
Clinical Implications: Opens avenues for pharmacologic or circuit-targeted modulation of arousal and ventilatory responses in conditions like sleep-disordered breathing or neonatal hypoxia vulnerability.
Key Findings
- A subset of Aldh1l1 astrocytes activates prior to sighs and during hypoxia.
- Opto/chemogenetic activation increases sigh-coupled arousal probability.
- Astrocyte activation enhances nearby catecholaminergic neuron Ca2+ transients before arousal.
4. Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
In 2,041 household contacts, a 5-day oral ensitrelvir course initiated within 72 hours reduced symptomatic PCR-confirmed COVID-19 to 2.9% vs 9.0% with placebo, with similar adverse events and no COVID-19 hospitalizations/deaths.
Impact: Delivers definitive RCT evidence supporting oral postexposure prophylaxis with a favorable safety profile—immediately actionable for outbreak and household management.
Clinical Implications: Supports considering ensitrelvir for eligible household contacts within 72 hours, particularly those at high risk; warrants guideline deliberation and variant-agnostic effectiveness monitoring.
Key Findings
- Primary outcome: 2.9% ensitrelvir vs 9.0% placebo by day 10 (RR 0.33).
- Adverse events comparable to placebo; serious events rare and balanced.
- No COVID-19–related hospitalizations or deaths occurred.
5. Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.
Multi-omic and functional analyses identify NKG2A as a dominant inhibitory checkpoint on NK cells in fibrotic lungs; targeting the HLA-E–NKG2A axis restores NK antifibrotic activity and reverses fibrosis in preclinical models.
Impact: Defines a druggable immune-escape mechanism maintaining fibrotic stroma and provides proof-of-concept for NK-based antifibrotic immunotherapy.
Clinical Implications: Supports early clinical development of NKG2A blockade and NK adoptive strategies with HLA-E/NKG2A as companion biomarkers for patient selection.
Key Findings
- NKG2A is the predominant inhibitory checkpoint on NK cells in fibrotic lungs.
- Senescent fibroblasts express HLA-E and suppress NK function via HLA-E–NKG2A interactions.
- Targeting the axis restores NK antifibrotic activity and reverses fibrosis in models.